Purine and pyrimidine (P2) receptors as drug targets

Journal of Medicinal Chemistry

Volumn 45, Issue 19, 2002, Pages 4057-4093

  Jacobson, Kenneth A ^a   Jarvis, Michael F ^b   Williams, Michael ^c  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b ABBOTT LABORATORIES   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 2 METHYLTHIOADENOSINE TRIPHOSPHATE; ABC TRANSPORTER; ADENINE; ADENINE NUCLEOTIDE DERIVATIVE; ADENOSINE TRIPHOSPHATE; CLOPIDOGREL; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HYPOXANTHINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; NICARDIPINE; PHOSPHOLIPASE C; PROTEIN KINASE; PURINE ANTAGONIST; PURINE P2 RECEPTOR; PURINE P2X RECEPTOR; PURINE P2Y RECEPTOR; PURINERGIC RECEPTOR STIMULATING AGENT; PYRIDOXAL 5 PHOSPHATE; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; PYRIMIDINE ANTAGONIST; PYRIMIDINE DERIVATIVE; RECEPTOR SUBTYPE; UNINDEXED DRUG; URACIL; URIDINE DIPHOSPHATE; URIDINE TRIPHOSPHATE;

DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MOLECULAR EVOLUTION; NEUROMODULATION; NUCLEOTIDE SEQUENCE; PURINE METABOLISM; PYRIMIDINE METABOLISM; REVIEW; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; ANIMALS; DRUG DESIGN; HUMANS; LIGANDS; PYRIMIDINES; RECEPTORS, PURINERGIC P2; URIDINE TRIPHOSPHATE;

EID: 0037068428     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020046y     Document Type: Review

References (455)

1. Purinergic nerves
2. A basis for distinguishing two types of purinergic receptor
3. Receptors for purines and pyrimidines
4. Pharmacology of cloned P2X receptors
5. Signaling by extracellular nucleotides and nucleosides
6. Agonists and antagonists acting at P2X receptors: Selectivity profiles and functional implications
7. Advances in signalling by extracellular nucleotides: The role and transduction mechanisms of P2Y receptors
8. ATP an extracellular signaling molecule between neurons and glia
9. P2X receptors
10. P2Y receptors: Structure and function
11. Purinergic and pyrimidinergic receptors as potential drug targets
12. P2 purinergic receptors: Modulation of cell function and therapeutic potential
13. Clinical opportunities in purinergic neuromodulation
14. Pharmacological characterization of P2 (nucleotide) receptors
15. Involvement of pyrimidinoceptors in the regulation of cell functions by uridine and by uracil nucleotides
16. ATP as a neurotransmitter
17. The control of the metabolism and the hormonal role of adenosine
18. The rotary enzyme of the cell: The rotation of F1-ATPase
19. Interplay of constitutively released nucleotides, nucleotide metabolism, and activity of P2Y receptors
20. 2+]i transients and oscillations in mouse fibroblasts are mediated by endogenously released ATP
21. Purinergic signalling: ATP release
22. Cooperation and competition in the evolution of ATP-producing pathways
23. Constitutive release of ATP and evidence for major contribution of ectonucleotide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations
24. Two novel families of ectonucleotidases: Molecular structures, catalytic properties and a search for function
25. Ectonucleotidases
26. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors
27. Phosphate is a specific signal for induction of osteopontin gene expression
28. The pharmacology of ATP-sensitive potassium channels
29. Ion channel genes and human neurological disease: Recent progress, prospects, and challenges
30. Mutual occlusion of P2X ATP receptors and nicotinic receptors on sympathetic neurons of the guinea-pig
31. State-dependent cross-inhibition between transmitter-gated cation channels
32. Intracellular ATP increases capsaicin-activated channel activity by interacting with nucleotide-binding domains
33. Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia
34. Ecto-protein kinases: Ecto-domain phosphorylation as a novel target for pharmacological manipulation?
35. Ecto-protein kinases as mediators for the action of secreted ATP in the brain
36. 1 nucleotide receptor in chick muscle: Its functional role in the regulation of acetylcholinesterase and acetylcholine receptor
37. Stage specific expression of P2Y receptors, ecto-apyrase and ecto-5′-nucleotidase in myeloid leukocytes
38. Expression of purinergic receptors (ionotropic P2X1-7 and metabotropic P2Y1-11) during myeloid differentiation of HL60 cells
39. Rapid up-regulation of P2Y messengers during granulocytic differentiation of HL-60 cells
40. 11 receptor
41. Regulation of bilary secretion by extracellular nucleotides
42. Cellular release of and response to ATP as key determinants of the set-point of signal transduction pathways
43. Perspective: Adenosine receptors: Pharmacology, structure activity relationships, and therapeutic potential
44. P2 purine and pyrimidine receptors: Emerging superfamilies of G-protein coupled and ligand gated ion channel receptors
45. 7 receptors
46. 7 receptor orthologs
47. Effects of caffeine on mammalian atrial muscle and its interaction with adenosine and calcium
48. The effects of adenosine and adenine nucleotides on the cyclic 3′-5′-phosphate content of guinea pig cerebral cortex slices
49. Alkylxanthines as research tools
50. Syntheses of nucleoside triphosphates
51. Structure activity relationships for adenine nucleotide receptors on mast cells, human platelets, and smooth muscle
52. Molecular recognition in P2 receptors: Ligand development aided by molecular modeling and mutagenesis
53. Recent developments in selective agonists and antagonists acting at purine and pyrimidine receptors
54. P1 and P2 purine and pyrimidine receptor ligands
55. 2-purinoceptor?
56. Extracellular ATP effects, sources and fate
57. Receptors responsive to extracellular pyrimidine nucleotides
58. Uridine and its nucleotides: Biological actions, therapeutic potential
59. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides
60. 2Y purinoceptors?
61. Nomenclature and classification of purinoceptors: A report from the IUPHAR subcommittee
62. Nomenclature and classification of purinoceptors: A report from the IUPHAR subcommittee
63. International Union of Pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits
64. A G protein-coupled receptor for UDP-glucose
65. Diadenosine polyphosphates, extracellular function and catabolism
66. ApnA, P4 and dinucleotide receptors: Are there too many?
67. Characterization of prejunctional purinoceptors on adrenergic nerves of the rat caudal artery
68. Initial sequencing and analysis of the human genome
69. 1 receptors
70. 7)
71. Identification of the platelet ADP receptor targeted by antithrombotic drugs
72. Molecular cloning of a novel P2 purinoceptor from human erythroleukemia cells
73. G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis
74. ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999
75. 1 receptor
76. Unique functional properties of a sensory neuronal P2X ATP-gated channel from zebrafish
77. 2X purinoceptors be classified pharmacologically?
78. Suramin analogues as subtype selective G protein inhibitors
79. Inhibition of human immunodeficiency virus type I reverse transcriptase by suramin-related compounds
80. 4 receptor
81. 1 receptor
82. 1 purinoceptors
83. The classification of seven transmembrane receptors in recombinant expression systems
84. 4 receptor channels
85. 3 receptor subunits can account for ATP-gated currents in sensory neurons
86. 5 receptor subunits reveals a novel ATP-gated ion channel
87. 5 subunits
88. The distribution of P2X receptor clusters on individual neurons in sympathetic ganglia and their redistribution on agonist activation
89. 3 receptors by diadenosine polyphosphates, α,β-meATP and ATP
90. Expression of multiple ATP subtypes during the differentiation and inflammatory activation of myeloid leukocytes
91. Should we be concerned about the state of hormone receptor classification?
92. Neuronal release of soluble nucleotidases and their role in neurotransmitter inactivation
93. Release of a soluble ATPase from the rabbit isolated vas deferens during nerve stimulation
94. Role of purines and pyrimidines in the central nervous system
95. Modulation of rat hippocampal dinucleotide receptor by adenosine receptor activation
96. Pharmacological analysis of ecto-ATPase inhibition: Evidence for combined enzyme inhibition and receptor antagonism in P2x-purinoceptor ligands
97. Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase
98. 3H]-α,β-methylene ATP in rat urinary bladder membranes
99. 35S]dATPαS binding sites in the adult rat neuraxis
100. 35S]-ADPγS as radioligands for inotropic and metabotropic P2 receptor binding
101. 1 receptor antagonist
102. 2 purinoreceptors in PC12 cells. Difference in purinoreceptor sensitivity in two PC12 cell lines
103. 1 receptor stimulate mitogen-activated protein kinases and induce apoptosis
104. + gated cation channels: Neuronal acid sensors in the NaC/DEG family of ion channels
105. 3 receptors form stable trimers: A novel structural motif of ligand-gated ion channels
106. Identification of a domain involved in ATP-gated ionotropic receptor subunit assembly
107. Perspective in Pharmacology. Neuronal nicotinic receptors as novel drug targets
108. 6 receptors and the distribution and properties of an extended family of ATPgated ion channels
109. 1/2 receptors show a novel sensitivity to extracellular pH
110. Properties of native P2X receptors in rat trigeminal mesencephalic nucleus neurons: Lack of correlation with known, heterologously expressed P2X receptors
111. The distribution of P2X receptor clusters on individual neurons in sympathetic ganglia and their redistribution on agonist activation
112. 1 receptor membrane redistribution and down-regulation visualized by using receptor-coupled green fluorescent protein chimeras
113. 2-green fluorescent protein receptors
114. A new class of ligand-gated ion channel defined by P2X for extracellular ATP
115. Characterization and chromosomal localization of a human P2X receptor from the urinary bladder
116. 1 receptor: Molecular cloning, tissue distribution, and localization to chromosome 17
117. 1 not P2T purinoceptors in human platelets
118. 1 receptors
119. New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor
120. A new class of ligand-gated ion channel defined by P2x receptor for extracellular ATP
121. Ionic permeability of, and divalent cation effects on, two ATP-gated cation channels (P2X receptors) expressed in mammalian cells
122. 2 receptor-channels and their role in calcium signaling in pituitary cells
123. 2 receptor
124. Differential distribution of two ATP-gated channels (P2X receptors) determined by immunocytochemistry
125. 2 subunits in adult and developing rat cochlear
126. Gene expression of P2X-receptors in the developing inner ear of the rat
127. 2 purinoceptor isoforms produced by alternative splicing in the adult rat vestibular end-organs
128. 2 receptor from the guinea pig organ of Corti
129. 2 receptor subunit of the ATP-gated ion channel in the cochlear: Implications for sound transduction and auditory neurotarnsmission
130. 2 receptor
131. 2 receptor
132. 2 purinoceptors
133. 2X purinoceptor expressed by a subset of sensory neurons
134. Purine-mediated signaling in pain and visceral perception
135. On the immunohistochemical distribution of ionotropic P2X receptors in the nucleus tractus solitarius of the rat
136. 3 is expressed by DRG neurons that terminate in inner lamina II
137. 3 receptor subunits in rat and monkey sensory neurons and their central terminals
138. 3-deficient mice display urinary bladder hyporeflexia and reduced nocifensive behavior
139. 3 receptors
140. 3 knock-out mice reveal a major sensory role for urothelially released ATP
141. Identification of gene expression profile of dorsal root ganglion in the rat peripheral axotomy model of neuropathic pain
142. ω-conotoxin GVIA potently inhibits the currents mediated by P2X receptors in rat DRG neurons
143. A P2X purinoceptor cDNA conferring a novel pharmacological profile
144. 4: An ATP-activated ionotropic receptor cloned from rat brain
145. Distinct localization of P2X receptors at excitatory postsynaptic specializations
146. 4 receptor orthologues
147. 4a receptors
148. Effect of erythromycin on ATP-induced intracellular calcium response in A549 cells
149. Molecular cloning and characterization of a novel ATP P2X receptor subtype from embryonic chick skeletal muscle
150. 5 isoforms
151. Frequent loss of expression or aberrant alternative splicing of P2XM, a p53-inducible gene, in soft tissue tumors
152. 7 receptors
153. 7. Cloning and expression of a human cDNA
154. 7 receptor in the immune system
155. Pore dilation of neuronal P2X receptor channels
156. Neuronal P2X transmitter-gated cation channels change their ion selectivity in seconds
157. 7-like cytolytic pore in human skin fibroblasts
158. 7 receptors
159. Oxidized ATP
160. 2Z receptor of human lymphocytes
161. Interleukin-1β maturation and release in response to ATP and nigericin
162. 7 receptor involvement
163. Rapid secretion of interleukin-1β by microvesical shedding
164. ATP receptors and giant cell formation
165. 7 receptor signalling complex
166. 7 contains multiple proteinand lipid-interaction motifs including a potential binding site for bacterial lipopolysaccharide
167. 7 receptors
168. 7 receptors
169. 7 receptor and relationship to function
170. P2Y receptors
171. 2Y3) activated preferentially by nucleoside diphosphates
172. 1 receptor stimulate mitogen-activated protein kinases and induce apoptosis
173. Identification of a novel human ADP receptor coupled to Gi
174. Dimerization of G-protein-coupled receptors
175. Heteromeric association creates a P2Y-like adenosine receptor
176. Cloning and functional expression of a brain G-protein-coupled ATP receptor
177. Expression cloning of an ATP receptor from mouse neuroblastoma cells
178. Expression of a cloned P2Y receptor that couples to phospholipase C
179. 1 receptor
180. 1 receptor of platelets without effect on the adenyl cyclase linked P2Y receptor
181. 1 receptor expression in Xenopus oocytes
182. 1-deficient mice
183. 1 receptor-null mice
184. Cloning of the rat P2U receptor and its potential role in coronary vasoladialtion
185. 2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy
186. Regulation of electrogenic anion secretion in normal and cystic fibrosis gallbladder mucosa
187. P2Y receptor subtypes differentially couple to inwardly rectifying potassium channels
188. A novel gliotic P2 receptor mediating cyclooxygenase-2 induction in rat and human astrocytes
189. P2Y receptors of MDCK cells: Epithelial cell regulation by extracellular nucleotides
190. 2 receptor gene expression on nucleotide regulation of murine epithelial Cl-transport
191. Cloning and functional expression of a human uridine nucleotide receptor
192. Cloning, expression, and chromosomal-localization of the human uridine nucleotide receptor gene
193. 4 receptor
194. 4 receptor
195. Molecular cloning and functional analysis of a novel P2 nucleotide receptor
196. 6 receptor
197. 6 nucleotide receptor mediates monocyte interleukin-8 production in response to UDP or lipopolysaccharide
198. +-currents in rat sympathetic neurons
199. 11 receptor
200. 11 receptor expression by human lymphocytes: Evidence for two cAMP-linked purinoceptors
201. 11 receptors in Madin Darby canine kidney cells
202. 1 is required to inhibit platelet aggregation in whole blood under flow
203. 2T receptor: A novel approach to antithrombotic therapy
204. Clinical experience with antithrombotic drugs acting on purine receptor pathways
205. Pharmacology of AR-C69931MX and related compounds: From pharmacological tools to clinical trials
206. 4-tetraphosphate: A novel antiplatelet agent
207. 12)
208. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs
209. An expressed sequence tag (EST) data mining strategy succeeding in the discovery of new G-protein coupled receptors
210. Discovery and mapping of ten novel G protein-coupled receptor genes
211. α1-coupled ADP receptor from human and mouse
212. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells
213. T-type receptor in brain capillary epithelial cells
214. 2 receptor
215. Roles of individual N-glycans for ATP potency and expression of the rat P2X1 receptor
216. Membrane topology of an ATP-gated ion channel (P2X receptor)
217. Identification of amino acid residues contributing to the pore of a P2X receptor
218. The first transmembrane domain of the P2X receptor subunit participates in the agonist-induced gating of the channel
219. 2 receptor
220. 2 ATP-gated channels
221. P2 receptor modeling and identification of ligand binding sites
222. 2U purinoceptors. Positively charged amino acids in transmembrane helices 6 and 7 affect agonist potency and specificity
223. 1 receptor: Molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites
224. 1 receptor: Structure-activity relationships and receptor docking
225. 1 receptor
226. 1 receptor in surface expression and activation processes
227. 1 receptor
228. Pharmacological characterization of recombinant human and rat P2X receptor subtypes
229. 2Y subtypes
230. Activity of novel adenine nucleotide derivatives as agonists and antagonists at recombinant rat P2X receptors
231. 2Y-subtypes
232. Direct assessment of renal microvascular responses to P2-purinoceptor agonists
233. Ontogeny of P2-purinoceptors in the longitudinal muscle and muscularis mucosae of the rat isolated duodenum
234. Suramin analogs, divalent cations and ATP-γ-S as inhibitors of ecto-ATPase
235. 2U-purinoceptors
236. The stable pyrimidines, UDPβS and UDPγS discriminate between P2 receptors that mediate vascular contraction and relaxation of the mesenteric artery
237. 1 receptor: Similarities to the platelet ADP receptor
238. 2-Thioether 5′-O-(1-thiotriphosphate)adenosine derivatives as new insulin secretagogues acting through P2Y-receptors
239. P2T receptor antagonists - Towards novel orally active antithrombotics
240. 1 receptor ligands
241. Selective agonism of group I P2X receptors by dinucleotides dependent on a single adenine moiety
242. Diadenosine polyphosphates: Extracellular function and catabolism
243. Diadenosine polyphosphate receptors from rat and guinea-pig brain to human nervous system
244. Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5′-polyphosphates
245. 2X purinoceptors
246. Suramin: A molecule with a broad spectrum of biological and therapeutic properties
247. 2 purinoceptors
248. The P2-purinoceptor antagonist suramin is a competitive antagonist at vasoactive intestinal peptide receptors in the rat gastric fundus
249. Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases
250. 2-purinoceptor subtypes and ecto-nucleotidases by small aromatic isothiocyanato-sulfonates
251. 2-purinoceptor subtypes and ecto-nucleotidases by compounds related to Evans blue and trypan blue
252. 2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin
253. 2X-purinoceptor antagonist in rat, hamster and rabbit isolated blood vessels
254. NF279: A novel potent and selective antagonist of P2X receptor-mediated responses
255. 1 receptor
256. 1 receptors
257. P2-receptor antagonists: IV. Blockade of P2-receptor subtypes and ecto-nucleotidases by compounds related to reactive blue 2
258. Discrimination between UTP-and P2-purinoceptor-mediated depolarization of rat superior cervical ganglia by 4,4′-diisothiocyanatostilbene-2,2′-disulphonate (DIDS) and uniblue A
259. 2X-purinoceptors by Trypan Blue in rat vas-deferens
260. 2Y-selective purinoceptor antagonist and an inhibitor of ecto-nucleotidase
261. 2 purinergic responses than reactive blue 2 (cibacron blue 3GA) in rat parotid acinar cells
262. Modulation of BzATP and formalin-induced nociception: Attenuation by the P2X receptor antagonist, TNP-ATP and enhancement by the allosteric modulator, cibacron blue
263. Blockade of ATP binding site of P2 purinoceptors in rat parotid acinar cells by isothiocyanate compounds
264. 2x-purinoceptors in rat vas deferens
265. Concomitant blockade of P2X-receptors and ectonucleotidases by P2-receptor antagonists: Functional consequences in rat vas deferens
266. PPADS a novel functionally selective antagonist of P2 purinoceptor-mediated responses
267. Inhibitory action of PPADS on relaxant responses to adenine nucleotides or electrical field stimulation in guinea-pig taenia coli and rat duodenum
268. Synthesis and structure activity relationships of pyridoxal-6-azoaryl-5′-phosphate and phosphonate derivatives as P2 receptor antagonists
269. 1 receptors
270. 3 receptors
271. 2Y-purinoceptors
272. 1 receptors
273. Pharmacological profile of the novel P2T-purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo
274. 2/3 receptors
275. 1 receptor antagonists
276. 1 receptor antagonists
277. 1 receptors
278. 1 receptor of platelets without effect on the adenyl cyclase lined P2Y receptor
279. 1-receptor
280. 7 nucleotide receptor: High selectivity for the human versus rat receptor homologues
281. 7 receptor antagonists: Tyrosyl derivatives synthesized using a sequential parallel synthetic approach
282. 2X purinoceptors in rat vas-deferens
283. 2 receptors
284. Identification and biological activity of the active metabolite of clopidogrel
285. 1 purinoceptor
286. Increased inhibitory action against adenosine 5′-triphosphate in the isolated taenia of the guinea-pig caecum by substitution in the A-ring of 2-phenylisatogen
287. Inhibition of ADP-induced platelet activation by 7-chloro-4-nitrobenz-2-oxa-1,3-diazole: Covalent modification of aggregin, a putative ADP receptor
288. Conopeptides: From deadly venoms to novel therapeutics
289. Neurokinin B potentiates ATP-activated currents in rat DRG neurons
290. 1 receptors
291. Characterization of subtypes of the P2X and P2Y families of ATP receptors in the foetal human heart
292. Cardiovascular purinoceptors
293. A dual function for adenosine 5′-triphosphate in the regulation of vascular tone
294. P2 receptor subtypes in the cardiovascular system
295. The regulation of vascular function by P2 receptors: Multiple sites and multiple receptors
296. P2 receptors in the cardiovascular system
297. Adenosine 5′-triphosphate: A P2-purinergic agonist in the myocardium
298. Role of the intima in cholinergic and purinergic relaxation of isolated canine femoral arteries
299. 2-purinoceptors in the cardiovascular system
300. 2-purinoceptors mediate both vasodilation (via the endothelium) and vasoconstriction of the isolated rat femoral artery
301. Roles of purines and pyrimidines in endothelium
302. 1-receptors in restance arteries
303. Downregulation of adenosine and P2X receptor-mediated cardiovascular responses in heart failure rats
304. Purinergic signaling and vascular cell proliferation and death
305. P2 receptors in the respiratory system
306. Effect of uridine 5′triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis
307. Cystic fibrosis gene and functions of CFTR implications of dysfunctional ion transport for pulmonary pathogenesis
308. Aerosolized Prolucin (uridine 5′-triphosphate, UTP) acutely enhances mucociliary clearence in mild chronic bronchitis (CB)
309. Therapeutic use of nucleotides in respiratory and opthalamic diseases
310. Evidence for the involvement of purinergic signaling in the control of respiration
311. Mechanism of action of ATP on canine pulmonary vagal C fibre nerve terminals
312. Activation of P2X receptors for adenosine triphosphate evokes cardiorespiratory reflexes in anesthetized rats
313. ATP modulates anti-IgE-induced release of histamine from human lung mast cells
314. Distinct modulation of evoked and spontaneous EPSCs by purinoceptors in nucleus tractus solitarii of the rat
315. Differential patterns of sympathic responses to selective stimulation of nucleus tractus solitarius purinergic receptor subtypes
316. ADP receptors of platelets and their inhibition
317. 1 receptor is an ADP receptor antagonized by ATP and expressed in megakaryoblastic cells
318. 1 purinoceptors on human platelets and megakaryoblastic cell lines
319. 1 receptors: Evidence for separate receptors stimulated by ATP and ADP on human platelets
320. Human ectoADPase/CD 39: Thromboregulation via a novel pathway
321. Extracellular ATP-dependent suppression of proliferation and induction of differentiation of human HL-60 leukemia cells by distinct mechanisms
322. 11 receptors in hematopoiesis
323. Molecular physiology of P2X receptors and ATP signaling at synapses
324. 2+ permeability and kinetics of glutamate receptors in rat medial habenula neurones: Implications for purinergic transmission in this nucleus
325. ATP as a presynaptic modulator
326. 3H] acetylcholine from the hippocampus and cerebral cortex of the rat: Role of the ectonucleotidases
327. 2 receptor activation of acetylcholine release from rat motor nerve terminals: Interaction with presynaptic nicotinic receptors
328. 2-receptor-mediated inhibition of noradrenaline release in the rat hippocampus
329. Adenosine 5′-triphosphate-induced dopamine release in the rat nucleus accumbens in vivo
330. 2 receptor-mediated inhibition of dopamine release in rat neostriatum
331. 2 receptor-mediated inhibition of serotonin release in rat brain cortex
332. 2x receptors elicits glutamate release from sensory neuron synapses
333. The functions of ATP receptors in the synaptic transmission in the hippocampus
334. Single GABAergic synaptic terminals from rat midbrain exhibit functional P2X and dinucleotide receptors, able to induce GABA secretion
335. Substance P NPY differentially potentiate ATP and adrenergic stimulated vasopressin and oxytocin release
336. 3-dependent mechanism
337. Adenosine and ATP in epilepsy
338. Effects of adenosine 5′-triphosphate and related agonists on cochlear function
339. 2 receptor mediates stimulation of parasensory cation absorption by cochlear outer sulcus cells and vestibular transitional cells
340. Physiological effects of extracellular nucleotides in the inner ear
341. Rapid correction of vestibular imbalance by intracochlear administration of ATP in a guinea pig model of unilateral peripheral vestibular disorder
342. Effects of diadenosine polyphosphates on tear secretion in New Zealand White rabbits
343. 7 receptors in Mueller cells of the rat retina
344. Expression of purinergic receptors in bipolar cells of the rat retina
345. Modulation of neuronal activity by glial cells in the retina
346. Nucleoside and nucleotide transmission in sensory systems
347. 3 receptor immuoreactive nerves in rat taste buds
348. The liberation of adenosine triphosphate on antidromic stimulation of sensory nerves
349. ATP excites a subpopulation of rat dorsal horn neurones
350. Is ATP a central synaptic mediator for certain primary afferent fibersfrom mammalian skin?
351. Observation on the algogenic actions of adenosine compounds on the human blister base preparation
352. ATP in human skin elicits a dose-related pain response under conditions of hyperalgesia
353. 6 receptors and the distribution and properties of an extended family of ATP-gated ion channels
354. 3 purinoceptor and IB4 binding sites
355. P2X receptor-mediated ionic currents in dorsal root ganglion neurons
356. Immunohistochemical evidence for ATP receptors in human dental pulp
357. 2X3 purinoceptors in sensory neurons in naive rats and following neuropathic injury
358. Ectopic purinergic sensitivity develops at sites of chronic nerve constriction injury in rat
359. 3 homomeric and heteromeric ion channels in nociceptive signaling and behavior
360. P2X receptors and nociception
361. Roles of purines in nociception and pain
362. Acute nociception mediated by hindpaw P2X receptor activation in the rat
363. The effects of inflammation and inflammatory mediators on nociceptive behavior induced by ATP analogues in the rat
364. Selective activation of nociceptors by P2X receptor agonists in normal and inflamed rat skin
365. Peripheral adenosine 5′-triphosphate enhances nociception in the formalin test via activation of a purinergic P2X receptor
366. Antinociceptive effect of intrathecally administered P2-purinoceptor antagonists in rats
367. 2/3 receptor signaling in capsaicin-insensitive primary afferent neurons
368. In vivo pathway of thermal hyperalgesia by intrathecal administration of α,β-methyleneATP in mouse spinal cord: Involvement of glutamate-NMDA receptor system
369. Evidence for the involvement of spinal endogenous ATP and P2X receptors in nociceptive responses caused by formalin and capsaicin in mice
370. 3 receptor antagonist blocks acetic acid-induced abdominal constriction in mice: Comparison reference analgesics
371. 3-deficient mice
372. Depletion of substance P from rat primary sensory neurons by ATP, an implication of P2X receptor-mediated release of substance P
373. Substance P abolishes the faciliatatory effects of ATP on spontaneous glycine release in neurons of the trigeminal nucleus pars caudalis
374. 3 antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats
375. Effects of spinally administered P2X receptor agonists and antagonists on the responses of dorsal horn neurons recorded in normal, carrageenan-inflamed and neuropathic rats
376. 2x receptors play little role in the maintinence of neuropathic hyperalgesia
377. Meningeal cells can communicate with astrocytes by calcium signaling
378. Purines in anesthesia
379. Release ofvasoactive substances from endothelial cells by shear stress and purinergic mechano-sensory transduction
380. P2X receptors in sensory neurons
381. Expanding field of purinergic signaling
382. ATP is released from guinea pig ureter epithelium on distension
383. Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells
384. Trophic actions of purines and pyrimidines
385. P2X receptor expression on astrocytes in the nucleus accumbens of rats
386. Trophic effects of purines in neurons and glial cells
387. Antagonists of P2 receptor prevent NGF-dependent neuritogenesis in PC12 cells
388. Extracellular ATP triggers tumor necrosis factor-α release from rat microglia
389. Exogenous ATP induces limited cell cycle progression of arterial smooth muscle cells
390. Purines and their role in apoptosis
391. 7 receptor of microglial cells: A novel immunomodulatory receptor
392. The P2 purinergic receptors of human dendritic cells: Identification and coupling to cytokine release
393. 7 nucleotide receptor and associated phospholipase C activity by lipopolysaccharide and IFN-γ in the human THP-1 monocytic cell line
394. Extracellular ATP activates transcription factor NF-κB through the P2Z purinoceptor by selectively targeting NF-κB p65 (RelA)
395. 7) receptors
396. Purinoceptors: Ontogeny and phylogeny
397. ATP transduces signals from ASGM1, a glycolipid that functions as a bacterial receptor
398. Purinergic innervation of the guinea-pig urinary bladder
399. Purinergic signaling in the lower urinary tract
400. Contribution of adrenergic and "purinergic" neurotransmission to contraction in rabbit detrusor
401. Neural control of the lower urinary tract
402. ATP vasoactive intestinal polypeptide relaxant responses in hamster isolated proximal urethra
403. Distribution of P2X receptors in the urinary bladder and the ureter of the rat
404. A quantitative analysis of purinoceptor expression in human fetal and adult bladders
405. The cholinergic and purinergic components of detrussor contracility in a whole rabbit bladder model
406. 2-purinoceptors to neurogenic contraction of rat urinary bladder smooth muscle
407. Alterations of cholinergic and purinergic signaling in a model of the obstructed bladder
408. Purinergic sensory neurotransmission in the urinary bladder: An in vitro study in the rat
409. 3 receptors in the rat and human urinary bladder
410. 5 receptor innervation in human detrusor from adults with urge incontinence
411. P2X receptors and their role in female detrusor instability
412. A quantitative analysis of purinoceptor expression in the bladders of patients with symptomatic outlet obstruction
413. Evidence for purinergic neurotransmission in human urinary bladder affected by interstistial cystitis
414. Activation and sensitization of low and high threshold afferent fibres mediated by P2X receptors in the mouse urinary bladder
415. P2X receptor immunoreactivity in the male genital organs of the rat
416. Expression of nucleotide P2X receptor subtypes during spermatogenesis in the adult rat testis
417. Effects of purines on rabbit corpus cavernosum contractile activity
418. Altered relaxant responses to adenosine and adenosine 5′-triphosphate in the corpus cavernosum from men and rats with diabetes
419. Purinergic signaling in the gut
420. Isolated rat hepatocytes can signal to other hepatocytes and bile duct epithelial cells by release of nucleotides
421. Volume-sensitive purinergic signaling in human hepatocytes
422. Emerging roles of purinergic signaling in gastrointestinal epithelial secretion and hepatobiliary function
423. Adenosine nucleotides in the bile
424. Regulation of biliary secretion through apical purinergic receptors in cultured rat cholangiocytes
425. Characterization of the biological effects of 2-methylthio-ATP on rat hepatocytes: Clear-cut differences from ATP
426. Actions of extracellular ATP and UTP in perfused rat liver
427. P2 purinoceptor agonists: New insulin secretogogues potentially useful in the treatment of non-insulin-dependent diabetes mellitus
428. Purinergic receptors and the pharmacology of type 2 diabetes
429. Adenosine diphosphate as an intracellular regulator of insulin secretion
430. Changes in the expression of P2 receptors in rat and mouse pancreas during development and aging
431. ATP is a potent stimulator of the activation and formation of rodent osteoclasts
432. P2 purinergic receptors on osteoblasts and osteoclasts: Potential targets for drug development
433. P2 nucleotide receptors in osteoclasts
434. 1 receptor on bone cells
435. Purinergic and pyrimidinergic receptor signaling in bone cells
436. P2-mediated responses in osteoclasts and osteoclast-like cells
437. ATP in the treatment of cancer
438. 2 following trauma-hemorrhage and resuscitation: Down regulation of inflammatory cytokine (TNF, IL-6) release
439. Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small-cell lung cancer
440. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
441. Cystic fibrosis hetero- and homozygosity is associated with inhibition of breast cancer growth
442. The risk of cancer among patients with cystic fibrosis
443. Expression of functional P2-purinergic receptors in primary cultures of human colorectal carcinoma cells
444. Effects ofextracellular nucleotides and nucleosides on prostate carcinoma cells
445. P2 receptor-mediated proliferative effects on astrocytes in vivo
446. 7 receptors by immunohistochemistry in rat stratified squamous epithelium
447. Prescription for an ailing pharmaceutical industry
448. Challenges in developing P2 purinoceptor-based therapeutics
449. Efficacy at G-protein-coupled receptors
450. Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery
451. 7 receptor channels
452. ATP-binding proteins as targets for drugs discovery
453. Calcium - A neglected key factor in arteriosclerosis. The pathogenic role of arterial calcium overload and its prevention by calcium antagonists